Improvements in glycaemic control and cholesterol concentrations associated with the Quality and Outcomes Framework: A regional 2-year audit of diabetes care in the UK

Diabetic Medicine

Volumn 27, Issue 3, 2010, Pages 354-359

  Oluwatowoju, I ^a   Abu, E ^b   Wild, S H ^c   Byrne, C D ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Audit; Delivery of care in UK; Diabetes care; Glycaemic control; Quality and outcomes framework QOF

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C; LIPID; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; GLYCEMIC CONTROL; HEALTH CARE DELIVERY; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MEDICAL AUDIT; UNITED KINGDOM; BLOOD; FEMALE; HEALTH SURVEY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; STANDARDS; TREATMENT OUTCOME;

ADULT; CHOLESTEROL; CHOLESTEROL, HDL; DELIVERY OF HEALTH CARE; DIABETES MELLITUS, TYPE 2; FEMALE; GREAT BRITAIN; HEALTH SURVEYS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPIDS; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 77949397728     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.02951.x     Document Type: Article

References (24)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
2. Abergavenny RD. GPs' diagnoses of type 2 diabetes rose by 50% in 10 years, study shows. Br Med J 2005; 331: 474.
3. Diabetes UK. Impact Report 2006. London: Diabetes UK, 2007: 1-24.
4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
5. Department of Health. Delivering Investment in General Practice: Implementing the New GMS Contract. London: Department of Health, 2003: 1-271.
6. BMA. Focus on QOF Payments. London, British Medical Association, 2007.
7. Department of Health. Annex A: Quality indicators - Summary of Points. London: Department of Health, 2009.
8. Diabetes Control Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
9. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
10. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
11. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
12. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
13. Medical Research Council/British Heart Foundation(MRC/BHF). Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
14. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
15. Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a UK study. Diabet Med 2005; 22: 554-562.
16. Campbell S, Reeves D, Kontopantelis E, Middleton E, Sibbald B, Roland M. Quality of primary care in England with the introduction of pay for performance. N Engl J Med 2007; 357: 181-190.
17. Tahrani AA, McCarthy M, Godson J, Taylor S, Slater H, Capps N et al. Diabetes care and the new GMS contract: the evidence for a whole county. Br J Gen Pract 2007; 57: 483-485.
18. National Diabetes Audit Executive Summary. Key Findings About the Quality of Care for People with Diabetes in England and Wales. Report for the Audit Period 2006-2007. Leeds, UK: NHS - The Information Centre for Health and Social Care, 2008.
19. Calvert M, Shankar A, McManus RJ, Lester H, Freemantle N. Effect of the quality and outcomes framework on diabetes care in the UK: retrospective cohort study. Br Med J 2009; 338: b1870.
20. Little RR, Rohlfing CL, Wiedmeyer HM, Myers GL, Sacks DB, Goldstein DE. The national glycohemoglobin standardization program: a five-year progress report. Clin Chem 2001; 47: 1985-1992.
21. Peat J, Barton B. Medical Statistics: A Guide to Data Analysis and Critical Appraisal, 1st edn. West Sussex, UK: Blackwell Publishing Ltd., BMJ Books, 2005.
22. Vaghela P, Ashworth M, Schofield P, Gulliford MC. Population intermediate outcomes of diabetes under pay-for-performance incentives in England from 2004 to 2008. Diabetes Care 2009; 32: 427-429.
23. Millett C, Netuveli G, Saxena S, Majeed A. Impact of pay for performance on ethnic disparities in intermediate outcomes for diabetes: a longitudinal study. Diabetes Care 2009; 32: 404-409.
24. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low-density lipoprotein particles. J Clin Invest 1993; 92: 141-146.